[go: up one dir, main page]

DE69941049D1 - Retrovirales verabreichungssystem - Google Patents

Retrovirales verabreichungssystem

Info

Publication number
DE69941049D1
DE69941049D1 DE69941049T DE69941049T DE69941049D1 DE 69941049 D1 DE69941049 D1 DE 69941049D1 DE 69941049 T DE69941049 T DE 69941049T DE 69941049 T DE69941049 T DE 69941049T DE 69941049 D1 DE69941049 D1 DE 69941049D1
Authority
DE
Germany
Prior art keywords
retroviral
delivery system
target site
nucleotide sequence
retroviral delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69941049T
Other languages
English (en)
Inventor
Kyriacos Andreou Mitraphanous
Deva Patil
Alan John Kingsman
Susan Mary Kingsman
Fiona Margaret Ellard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9811153A external-priority patent/GB2337520B/en
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Application granted granted Critical
Publication of DE69941049D1 publication Critical patent/DE69941049D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13061—Methods of inactivation or attenuation
    • C12N2740/13062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16045—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045—RNA rev transcr viruses
    • C12N2810/6054—Retroviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081—Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Passenger Equipment (AREA)
  • Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
DE69941049T 1998-05-22 1999-05-21 Retrovirales verabreichungssystem Expired - Lifetime DE69941049D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9811153A GB2337520B (en) 1998-05-22 1998-05-22 Delivery system
US9314998P 1998-07-17 1998-07-17
PCT/GB1999/001607 WO1999061639A2 (en) 1998-05-22 1999-05-21 Retroviral delivery system

Publications (1)

Publication Number Publication Date
DE69941049D1 true DE69941049D1 (de) 2009-08-13

Family

ID=26313732

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69941049T Expired - Lifetime DE69941049D1 (de) 1998-05-22 1999-05-21 Retrovirales verabreichungssystem

Country Status (10)

Country Link
EP (1) EP1080216B1 (de)
JP (1) JP4612950B2 (de)
KR (1) KR20010074493A (de)
CN (1) CN1325653C (de)
AT (1) ATE435297T1 (de)
AU (1) AU763007B2 (de)
CA (1) CA2328491A1 (de)
DE (1) DE69941049D1 (de)
GB (1) GB2351290A (de)
WO (1) WO1999061639A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1238092B1 (de) * 1999-12-14 2007-01-24 Novartis AG Auf dem rinderimmunschwächevirus (biv) basierte vektoren
GB0024550D0 (de) 2000-10-06 2000-11-22 Oxford Biomedica Ltd
JP2004517057A (ja) * 2000-11-03 2004-06-10 オックスフォード バイオメディカ（ユーケイ）リミテッド ベクターシステム
US20020168760A1 (en) * 2001-03-13 2002-11-14 Dornburg Ralph C. Retroviral vectors for gene transfer into neuronal cells
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
FR2825372B1 (fr) 2001-06-01 2004-06-18 Centre Nat Rech Scient Pseudotypage des vecteurs vih-1 par des enveloppes de rhabdovirus
DE60230641D1 (de) * 2001-09-14 2009-02-12 Oxford Biomedica Ltd Lentivirale vektoren zur behandlung von schmerzen
SI1504108T1 (sl) 2002-02-01 2013-07-31 Oxford Biomedica (Uk) Limited Lentiviralni vektor
AU2003271883A1 (en) * 2002-10-04 2004-04-23 Oxford Biomedica (Uk) Limited Vector system
CN101014710A (zh) * 2004-09-07 2007-08-08 株式会社Macrogen 基于caev的载体系统
JP4926168B2 (ja) 2005-05-13 2012-05-09 オックスフォード バイオメディカ（ユーケー）リミテッド ペプチド
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
EP2307551B1 (de) 2008-06-18 2016-12-14 Oxford BioMedica (UK) Limited Aufreinigung retroviraler vektoren
EA032403B1 (ru) * 2009-07-24 2019-05-31 Иммьюн Дизайн Корп. Лентивирусные векторы, псевдотипированные гликопротеином оболочки вируса синдбис
WO2011148194A1 (en) 2010-05-28 2011-12-01 Oxford Biomedica (Uk) Ltd Delivery of lentiviral vectors to the brain
AU2011336467A1 (en) 2010-12-01 2013-07-04 Spinal Modulation, Inc. Agent delivery systems for selective neuromodulation
GB201118636D0 (en) 2011-10-28 2011-12-07 Oxford Biomedica Ltd Nucleotide sequence
EP3567112A1 (de) 2013-06-13 2019-11-13 Translate Bio, Inc. Virenproduktion auf messenger-rna-basis
GB201318804D0 (en) 2013-10-24 2013-12-11 Adaptimmune Ltd Vectors for transgene expression
GB201715052D0 (en) * 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
WO2020183374A1 (en) 2019-03-10 2020-09-17 Axovant Sciences Gmbh Gene therapy compositions and methods for treating parkinson's disease
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0261940A3 (de) * 1986-09-23 1989-07-05 Applied Biotechnology, Inc. Pseudorabies-Impfstoffe und DNS-Vektoren zur Rekombination mit Poxviren
JPH06500232A (ja) * 1990-08-15 1994-01-13 サリオン・バイオロジクス・コーポレイシヨン 自己集合性複製欠陥型ハイブリッドウイルス粒子
JP3547129B2 (ja) * 1991-02-19 2004-07-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 変更宿主域を有するウィルス粒子
WO1993001833A1 (en) * 1991-07-17 1993-02-04 Commonwealth Scientific And Industrial Research Organisation Improved vaccine
AU3434393A (en) * 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
ZA937164B (en) * 1992-09-28 1994-05-23 Commw Scient Ind Res Org Delivery system
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
AU3635695A (en) * 1994-09-19 1996-04-09 Board Of Trustees Of The Leland Stanford Junior University Methods for genetically modifying hematopoietic stem cells
US5739018A (en) * 1996-08-07 1998-04-14 The Regents Of The University Of California Packaging cell lines for pseudotyped retroviral vectors

Also Published As

Publication number Publication date
WO1999061639A3 (en) 2000-01-27
WO1999061639A2 (en) 1999-12-02
CN1302334A (zh) 2001-07-04
ATE435297T1 (de) 2009-07-15
EP1080216B1 (de) 2009-07-01
KR20010074493A (ko) 2001-08-04
CN1325653C (zh) 2007-07-11
JP4612950B2 (ja) 2011-01-12
CA2328491A1 (en) 1999-12-02
GB0024915D0 (en) 2000-11-22
GB2351290A (en) 2000-12-27
EP1080216A2 (de) 2001-03-07
AU763007B2 (en) 2003-07-10
JP2002518997A (ja) 2002-07-02
AU3947399A (en) 1999-12-13

Similar Documents

Publication Publication Date Title
ATE435297T1 (de) Retrovirales verabreichungssystem
UA32548C2 (uk) Ізольована послідовність днк, що кодує epsps фермент, ізольована послідовність днк, що кодує білок, який виявляє epsps активність, рекомбінантна двониткова молекула днк, спосіб одержання генетично трансформованих рослин
NO20014364L (no) Ny cytokin-zalphall-ligand
NO20043419L (no) Nytt cytokin, zcytor17-ligand
CY1113185T1 (el) Μεθοδοι συνενωσης αποδεκτη πεπτιδιου
NO2013009I1 (no) Alipogen tiparvovec
WO2001064835A8 (en) Novel nucleic acids and polypeptides
HUP0100094A1 (hu) Új felületi antigén
ES8705521A1 (es) Un metodo de producir un polipetido similar a factor de necrosis de tumores (tnf) de mamiferos.
FI965031A0 (fi) Sieni, jossa AreA-geeni on muunnettu, ja Aspergillus oryzaesta peräisin oleva areA-geeni
EA200200565A1 (ru) Применение клеток, трансфицированных днк, кодирующей лиганд мнс класса ii, и способ получения таких клеток
AU3808995A (en) Nucleotide sequences of HIV-1 group (or subtype) O retrovirus antigens
DK0599868T3 (da) Polyphenoloxidase-gener
NO974035D0 (no) En ny vestfaktor og en genetisk sekvens som koder for denne
GB0202569D0 (en) Delivery means
BG101038A (bg) Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък
DE69629808D1 (de) Promtors für gen expression
IS6433A (is) Aðferð til framleiðslu á sítalóprami
WO2002022663A3 (en) Stress resistant retroviruses
DK1015415T3 (da) Nye stereoselektive fremgangsmåder til fremstilling af gabapentin-analoger
DE69823188D1 (de) Klonierung der udp-galaktose-epimerase
DE60229966D1 (de) Diabetesmodell
WO2001096535A3 (de) Nukleinsäure codierend eine bindungsstelle einer protein kinase der mitogenen signalisierungskaskade für ein die glykolyse katalysierendes enzym
WO2002083727A3 (de) Nukleinsäuresequenzen von hyperplasien und tumoren der schilddrüse
EA200100440A1 (ru) Ген prv-1 и его применение

Legal Events

Date Code Title Description
8364 No opposition during term of opposition